Collaborating with clinical focus
This article was originally published in Scrip
For some time now pharmaceutical industry chiefs have struggled with rising research costs, longer development times, falling R&D productivity and increasing pressures on operating margins. For the past decade, we have seen pharma companies reorganise their R&D structures, reduce their dependency on in-house R&D, smooth out chinks in the clinical supply chain and even focus on more targeted approaches to try and iron out the inefficiencies of drug research. With not much too show for their endeavours.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.